🎉 Congratulations to BIO member Neurocrine Biosciences on the FDA approval of CRENESSITY, the first new treatment available in 70 years for patients with classic congenital adrenal hyperplasia (CAH).
Our treatment for classic congenital adrenal hyperplasia has been approved by the U.S. FDA for use in adults and children, ages 4 and older. It is a first-in-class treatment developed for individuals living with classic CAH and represents a significant shift in the treatment landscape. Learn more about the impact of this approval for the CAH community. https://lnkd.in/ge_hpE8Q